| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| Other Sizes |
|
| ln Vivo |
Ambroxol (NA-872; 1, 3, 4, 5 mM in drinking water for 12 days) causes disease in transgenic mice expressing the heterozygous L444P mutation in the murine glucocerebrosidase 1 gene, and in mice overexpressing human α-synuclein [2].
|
|---|---|
| ADME/Pharmacokinetics |
Metabolism / Metabolites
Ambroxol has known human metabolites that include 4-Aminocyclohexanol, cis- and 2-Amino-3,5-dibromobenzaldehyde. |
| References |
[1]. Vojo Deretic, et al. Enhancement of lung levels of antibiotics by ambroxol and bromhexine. Expert Opin Drug Metab Toxicol. 2019 Mar;15(3):213-218.
[2]. Anna Migdalska-Richards, et al. Ambroxol effects in glucocerebrosidase and α-synuclein transgenic mice. Ann Neurol. 2016 Nov;80(5):766-775. |
| Additional Infomation |
Ambroxol is an aromatic amine.
Ambroxol has been reported in Justicia adhatoda with data available. A metabolite of BROMHEXINE that stimulates mucociliary action and clears the air passages in the respiratory tract. It is usually administered as the hydrochloride. See also: Ambroxol (annotation moved to). |
| Molecular Formula |
C13H18N2OBR2
|
|---|---|
| Molecular Weight |
378.10282
|
| Exact Mass |
375.978
|
| CAS # |
18683-91-5
|
| Related CAS # |
Ambroxol hydrochloride;23828-92-4
|
| PubChem CID |
2132
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.7±0.1 g/cm3
|
| Boiling Point |
468.6±45.0 °C at 760 mmHg
|
| Melting Point |
233-234ºC
|
| Flash Point |
237.2±28.7 °C
|
| Vapour Pressure |
0.0±1.2 mmHg at 25°C
|
| Index of Refraction |
1.654
|
| LogP |
2.91
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
18
|
| Complexity |
259
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O[C@H]1CC[C@H](NCC2=CC(Br)=CC(Br)=C2N)CC1
|
| InChi Key |
JBDGDEWWOUBZPM-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C13H18Br2N2O/c14-9-5-8(13(16)12(15)6-9)7-17-10-1-3-11(18)4-2-10/h5-6,10-11,17-18H,1-4,7,16H2
|
| Chemical Name |
4-[(2-amino-3,5-dibromophenyl)methylamino]cyclohexan-1-ol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 200 mg/mL (~528.96 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 5 mg/mL (13.22 mM) in 5% DMSO + 95% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.61 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (6.61 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: ≥ 2.5 mg/mL (6.61 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL corn oil and mix evenly. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6448 mL | 13.2240 mL | 26.4480 mL | |
| 5 mM | 0.5290 mL | 2.6448 mL | 5.2896 mL | |
| 10 mM | 0.2645 mL | 1.3224 mL | 2.6448 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT06614894 | Not yet recruiting | Drug: Ambroxol Hydrochloride 30 mg tablet - 9 mg/kg/day Drug: Ambroxol Hydrochloride 30 mg tablet - 18 mg/kg/day Drug: Ambroxol Hydrochloride 30 mg tablet - 27 mg/kg/day |
MPS3 Sanfilippo Syndrome |
Ozlem Goker-Alpan | 2024-12-01 | Phase 2 Phase 3 |
| NCT02036775 | Completed | Drug: Lasolvan tablet Drug: Lasolvan tablet Drug: Lasolvan tablet |
Healthy | Boehringer Ingelheim | 2014-03 | Phase 1 |
| NCT05778617 | Not yet recruiting | Drug: Ambroxol Hydrochloride (420mg) Drug: Placebo |
Parkinson Disease | University College, London | 2024-10 | Phase 3 |
| NCT05287503 | Active, not recruiting | Drug: Ambroxol Hydrochloride Drug: Placebo |
GBA Gene Mutation Parkinson Disease |
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta | 2022-02-15 | Phase 2 |
| NCT02941822 | Completed | Drug: Ambroxol | Parkinson Disease | University College, London | 2016-12 | Phase 2 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
